Y. Nikiforov

Endocrinology, Diabetes and Metabolism · 2003–2014

A researcher in the Science corpus: 10 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Endocrinology, Diabetes and Metabolism — 96 citations into it
• Molecular Biology — 86 citations into it
• Genetics — 32 citations into it
• Oncology — 28 citations into it

Whom Y. Nikiforov trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Mingzhao Xing
2. M. Nikiforova
3. Michael Mingzhao Xing
4. Zubair Baloch

Who trusts Y. Nikiforov overall

1. D. Cooper

Papers from Y. Nikiforov's perspective

Ordered by how strongly the researchers Y. Nikiforov trusts endorse each paper. Same corpus, a different order for every researcher.

1. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status (Nature)
2. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce (Thyroid)
3. Mutations of the BRAF gene in human cancer (Nature)
4. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. (Cancer Research)
5. BRAF mutation in papillary thyroid carcinoma. (Journal of the National Cancer Institute)
6. BRAF mutation in thyroid cancer. (Endocrine-Related Cancer)
7. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. (Journal of Clinical Endocrinology and Metabolism)
8. The Raf/MEK/ERK pathway: new concepts of activation (Biology of the Cell)
9. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. (Science)
10. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. (Journal of Clinical Endocrinology and Metabolism)

Their papers

• Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. (2011) — 703 citations
• Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) — 2,692 citations
• American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (2012) — 846 citations
• Molecular genetics and diagnosis of thyroid cancer (2011) — 986 citations
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009) — 11,512 citations
• Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. (2009) — 659 citations
• MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. (2008) — 611 citations
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (2003) — 1,066 citations
• RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. (2003) — 718 citations
• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. (2003) — 1,567 citations